Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.82 |
| ▸ | DRD4 | P21917 | 2/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31486979 | 0.93 | SIGMAR1 (0.71) | SIGMAR1DRD4CHRM1OPRM1 | |
| SCHEMBL10340306 | 0.89 | SIGMAR1 (0.67) | SIGMAR1DRD4CHRM1CXCR3MAOA | |
| SCHEMBL25815883 | 0.88 | SIGMAR1 (0.80) | SIGMAR1DRD4CXCR3HTR2AACHE | |
| SCHEMBL10648926 | 0.88 | SIGMAR1 (0.80) | SIGMAR1DRD4CHRM1CXCR3MAOA | |
| SCHEMBL13929176 | 0.87 | SIGMAR1 (0.64) | SIGMAR1CHRM1MAOAMAOBEPHX2 | |
| SCHEMBL27430491 | 0.87 | SIGMAR1 (0.79) | SIGMAR1DRD4CXCR3HTR2AACHE | |
| SCHEMBL11576999 | 0.86 | SIGMAR1 (0.65) | SIGMAR1DRD4MAOAMAOBBCHE | |
| SCHEMBL26097425 | 0.86 | SIGMAR1 (0.70) | SIGMAR1DRD4CHRM1CXCR3EPHX2 | |
| SCHEMBL17512172 | 0.86 | SIGMAR1 (0.70) | SIGMAR1DRD4CHRM1CXCR3HTR2A | |
| SCHEMBL27904589 | 0.86 | SIGMAR1 (0.60) | SIGMAR1CHRM1MAOAMAOBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102172345-B | Method for allocating the fast dispersing dosage form comprising at least one isinglass based on molecular weight selection | R.P.谢勒技术有限公司 | 2018-05-04 | — | — | CN | disclosed |
| EP-3145503-A1 | METHOD FOR ADJUSTING THE RELEASE OF ACTIVE AGENT IN A TRANSDERMAL DELIVERY SYSTEM | LTS Lohmann Therapie-Systeme AG (DE) | 2017-03-29 | — | — | EP | disclosed |
| CN-106456567-A | Method for modulating the release of active agents in transdermal delivery systems | LTS勒曼治疗系统股份公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106456568-A | Transdermal delivery system including interface mediator | LTS勒曼治疗系统股份公司 | 2017-02-22 | — | — | CN | disclosed |
| WO-2015177209-A1 | METHOD FOR ADJUSTING THE RELEASE OF ACTIVE AGENT IN A TRANSDERMAL DELIVERY SYSTEM | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2015-11-26 | — | — | WO | disclosed |
| EP-2646107-A2 | AGENT DELIVERY SYSTEMS FOR SELECTIVE NEUROMODULATION | Spinal Modulation Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012075337-A2 | DIRECTED DELIVERY OF AGENTS TO NEURAL ANATOMY | SPINAL MODULATION, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| EP-1708686-A4 | GENERALLY LINEAR EFFERVESCENT ORAL FENTANYL DOSAGE FORM AND METHODS OF ADMINISTERING | CIMA LABS INC (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1708686-A2 | GENERALLY LINEAR EFFERVESCENT ORAL FENTANYL DOSAGE FORM AND METHODS OF ADMINISTERING | CIMA LABS INC. (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005065319-A2 | GENERALLY LINEAR EFFERVESCENT ORAL FENTANYL DOSAGE FORM AND METHODS OF ADMINISTERING | CIMA LABS INC. (US) | 2005-07-21 | — | — | WO | disclosed |